Natco Pharma Q3 Results: Revenue Jumps 36% YoY, PAT Up 14% Amid Mixed 9M FY26

Natco Pharma Q3 Results

NATCO Pharma delivered its Q3 FY26 results on February 12, 2026, showing consolidated revenue from operations at ₹647 crore, marking a solid 36 percent jump from ₹475 crore in the same quarter last year, even as total income reached ₹705 crore. Profit after tax came in at ₹151 crore, reflecting a 14 percent year-on-year increase, which feels reassuring for a company navigating the usual ups and downs of the pharma world.

The nine-month picture tells a more mixed story, with revenue inching up to ₹3,339 crore from ₹3,209 crore, yet net profit easing to ₹1,150 crore compared to the stronger prior period, largely because of an exceptionally high base in the previous quarter where one-time factors boosted numbers. On a standalone basis, revenue grew to ₹529 crore in Q3, up from ₹408 crore, while PAT stood at ₹107 crore.

The formulations export business remained the standout performer, driving much of the quarterly momentum, though the agro chemicals segment continued to post losses at ₹10 crore or so, albeit narrower than before.

Shareholders got some welcome news with the board declaring a third interim dividend of ₹1.50 per share, payable later this month. Strategic moves added further color: the company completed its acquisition of a 35.75 percent stake in South Africa's Adcock Ingram, contributing a modest share of profit this quarter, and it announced plans for a new wholly owned subsidiary in Chile to expand its global footprint.

Talks around potentially demerging the agro chemicals business into a separate entity are also underway, a step that could unlock more focused growth in the core pharma operations. Leadership transitions included the appointment of a new CFO and an executive vice president for the pharma division, signaling a fresh chapter as key directors received re-appointments for another year.

For investors tracking natco pharma q3 results, the quarterly revenue surge highlights resilience in the domestic and export formulations segments amid steady demand for complex generics. The QoQ drop from Q2's outsized figures was sharp, as often happens when exceptional items fade, but the underlying business trajectory stays positive with healthy margins around 31 percent on EBITDA including other income.

The company's ongoing investments in international markets and product pipeline suggest it is positioning itself for steadier long-term expansion, even if quarterly swings remind everyone that pharma earnings rarely move in straight lines. Overall, these numbers paint a picture of a firm steadily advancing in a competitive landscape, rewarding patience with consistent dividends and measured global bets.

Below is the official PDF for Natco Pharma Q3 Results

Disclaimer: This article on Natco Pharma Q3 FY26 results is for informational and educational purposes only and is not investment, tax, or legal advice. Financial figures may be updated or revised by the company. Readers should independently verify data and consult a qualified advisor before making any investment decisions.